Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Research Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231190644. doi: 10.1177/15330338231190644.
The 5-year recurrence rate of thermal ablation for hepatocellular carcinoma (HCC) is high, and whether this treatment strategy induces systemic immune response remains elusive. This study aimed to investigate the effects of thermal ablation on HCC patients' cytokine profiles and to explore the correlation of cytokine profiles with tumor recurrence after ablation. A total of 22 HCC patients were included in this prospective study. The levels of 27 cytokines in the peripheral blood of HCC patients were measured before ablation (baseline), week 1, and week 4 after ablation using a Bio-Plex Pro Human Cytokine 27-plex Assay kit. Cytokines showed different dynamic changing trends after ablation treatment. It was found that the level of IL-6 was significantly elevated at week 1 and returned to the baseline level at week 4 after ablation. The level of IL-10 was slightly reduced at week 1 and significantly decreased at week 4. The levels of MCP-1, macrophage inflammatory protein-1β (MIP-1β), and TNF-α were similarly reduced at week 1 and increased at week 4. The levels of IL-17, platelet-derived growth factor-BB (PDGF-BB), and regulated upon activation, normal T cell expressed and secreted (RANTES) showed little to no change at week 1 while an observable increase at week 4. Patients with a high IL-10 level (2.99 pg/ml) at baseline and low levels of TNF-α (20.4 pg/ml), PDGF-BB (107.78 pg/ml), and RANTES (2303.94 pg/ml) at week 4 were at risk of tumor recurrence during 1-year follow-up. The results suggested that thermal ablation activated systemic immune responses by changing the levels of cytokines. The results also demonstrated that measurement of IL-10 at baseline, TNF-α, PDGF-BB, and RANTES at week 4 after ablation might predict the risk of tumor recurrence.
肝癌(HCC)热消融治疗的 5 年复发率较高,但其是否诱导全身免疫反应仍不清楚。本研究旨在探讨热消融对 HCC 患者细胞因子谱的影响,并探讨细胞因子谱与消融后肿瘤复发的相关性。
这项前瞻性研究共纳入 22 例 HCC 患者。使用 Bio-Plex Pro Human Cytokine 27-plex Assay 试剂盒,在消融前(基线)、消融后 1 周和 4 周测量 HCC 患者外周血中 27 种细胞因子的水平。
消融治疗后细胞因子呈现出不同的动态变化趋势。结果发现,IL-6 水平在消融后 1 周显著升高,在 4 周时恢复至基线水平。IL-10 水平在 1 周时略有下降,在 4 周时显著下降。MCP-1、巨噬细胞炎症蛋白-1β(MIP-1β)和 TNF-α的水平在 1 周时同样降低,在 4 周时升高。IL-17、血小板衍生生长因子-BB(PDGF-BB)和活化正常 T 细胞表达和分泌的调节因子(RANTES)在 1 周时几乎没有变化,而在 4 周时则明显增加。
基线时 IL-10 水平较高(2.99pg/ml),4 周时 TNF-α、PDGF-BB 和 RANTES 水平较低(分别为 20.4pg/ml、107.78pg/ml 和 2303.94pg/ml)的患者在 1 年随访期间有肿瘤复发的风险。
结果表明,热消融通过改变细胞因子水平激活了全身免疫反应。研究结果还表明,在消融后 4 周测量 IL-10、TNF-α、PDGF-BB 和 RANTES 可能有助于预测肿瘤复发的风险。